Genomic Alterations in Pulmonary Carcinoid Tumors: A Targeted Analysis of Gene Rearrangements and Oncogenic Mutations.
- 1Department of Pathology, HUS Diagnostic Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
- 2Department of Genetics, HUS Diagnostic Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
- 3Applied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Abstract
Introduction
Pulmonary carcinoids (PCs) are rare, well-differentiated, neuroendocrine lung tumors with limited treatment options for advanced disease, underscoring the need for targeted therapies. PCs typically exhibit a low mutational burden. Although MEN1 and chromatin-modifier mutations are known contributors, potentially actionable alterations remain poorly characterized. To better define therapeutic opportunities, we evaluated oncogenic fusions and variants across 17 cancer-associated genes in a large retrospective PC cohort.Methods
Formalin-fixed, paraffin-embedded primary tumors from Helsinki University Hospital (n = 119, collected between 1990 and 2020) were subjected to targeted RNA-based fusion and variant analysis using the Archer FusionPlex Lung v2 assay.Results
The most frequent recurrent genetic rearrangements involved ALK (n = 5), BRAF (n = 3), FGFR2 (n = 3), and NTRK3 (n = 2), each featuring diverse fusion partners. Variant analysis identified BRAF, EGFR, FGFR1, and FGFR3 as the most frequently mutated genes, although only 2.2% (n = 4) of all detected variants were classified as oncogenic. Notably, 66.7% of all oncogenic or likely oncogenic variants occurred in BRAF and EGFR. Oncogenic variants were identified in ALK, BRAF, EGFR, and ERBB2. Although all FGFR1-3 variants were of uncertain significance, their frequency (34.1% of all detected variants), together with the three FGFR2 fusions, suggested that FGFR alterations may be biologically relevant in PCs.Conclusion
Despite the typically muted genomic landscape of PCs, our study revealed a small yet therapeutically relevant subset of alterations. The findings further characterized the molecular profile of PCs and identified potentially actionable molecular subgroups. While these alterations were not associated with disease-specific survival or metastatic status, they support consideration of molecular profiling in selected patients with advanced disease.
Related
- Synchronous lung adenocarcinoma and pulmonary carcinoid tumorlets in different lobes: a case report
- WRN deficiency generates oncogenic rearrangements at TA-rich tandem repeats
- Pulmonary Carcinoid Tumors (Lung Carcinoids): Current Concepts in Diagnosis and Management
- Oncogenic PIK3CA mutations cause lineage-selective niche corruption
- Oncogenic mutations in non-small cell lung cancer: from molecular mechanisms to clinical practice.
BibTeX
@article{niinimaki2026genomic,
title = {{Genomic Alterations in Pulmonary Carcinoid Tumors: A Targeted Analysis of Gene Rearrangements and Oncogenic Mutations.}},
author = {Jenni Niinimäki and Soili Kytölä and Ari Ristimäki and Johanna Arola and Tiina Vesterinen},
journal = {Cancer medicine},
year = {2026},
month = oct,
doi = {10.1002/cam4.72441},
url = {https://europepmc.org/article/MED/42952377},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Genomic Alterations in Pulmonary Carcinoid Tumors: A Targeted Analysis of Gene Rearrangements and Oncogenic Mutations.
AU - Jenni Niinimäki
AU - Soili Kytölä
AU - Ari Ristimäki
AU - Johanna Arola
AU - Tiina Vesterinen
PY - 2026
DA - 2026/10/29
JO - Cancer medicine
DO - 10.1002/cam4.72441
UR - https://europepmc.org/article/MED/42952377
AB - Introduction Pulmonary carcinoids (PCs) are rare, well-differentiated, neuroendocrine lung tumors with limited treatment options for advanced disease, underscoring the need for targeted therapies. PCs typically exhibit a low mutational burden. Although MEN1 and chromatin-modifier mutations are known contributors, potentially actionable alterations remain poorly characterized. To better define therapeutic opportunities, we evaluated oncogenic fusions and variants across 17 cancer-associated genes in a large retrospective PC cohort.Methods Formalin-fixed, paraffin-embedded primary tumors from Helsinki University Hospital (n = 119, collected between 1990 and 2020) were subjected to targeted RNA-based fusion and variant analysis using the Archer FusionPlex Lung v2 assay.Results The most frequent recurrent genetic rearrangements involved ALK (n = 5), BRAF (n = 3), FGFR2 (n = 3), and NTRK3 (n = 2), each featuring diverse fusion partners. Variant analysis identified BRAF, EGFR, FGFR1, and FGFR3 as the most frequently mutated genes, although only 2.2% (n = 4) of all detected variants were classified as oncogenic. Notably, 66.7% of all oncogenic or likely oncogenic variants occurred in BRAF and EGFR. Oncogenic variants were identified in ALK, BRAF, EGFR, and ERBB2. Although all FGFR1-3 variants were of uncertain significance, their frequency (34.1% of all detected variants), together with the three FGFR2 fusions, suggested that FGFR alterations may be biologically relevant in PCs.Conclusion Despite the typically muted genomic landscape of PCs, our study revealed a small yet therapeutically relevant subset of alterations. The findings further characterized the molecular profile of PCs and identified potentially actionable molecular subgroups. While these alterations were not associated with disease-specific survival or metastatic status, they support consideration of molecular profiling in selected patients with advanced disease.
SN - 2045-7634
ER -